Search
Lucid Diagnostics Inc
LUCDAdd to Watchlist
1.070USD
+0.020+1.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
140.09MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.90%
5 Days
-0.93%
1 Month
+4.90%
6 Months
-4.46%
Year to Date
-1.83%
1 Year
+3.88%
Key Figures
1.040Open
1.080High
791.73KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.60%Turnover Ratio
1.050Prev. Close
1.040Low
668.04KTurnover
LossP/E Static
-4.93P/B
0.00%Div Yield TTM
-134.61%ROA
1.62952wk High
0.50Volume Ratio
-53.02MNet Profit
130.92MShares
-0.3373EPS TTM
1.09Beta
-4989.67%ROE
0.90052wk Low
3.81%Amplitude
-37.74%Gross Margin
140.09MMarket Cap
0.72Reward/Risk
4.07%Risk Rate
TradingKey Stock Score of Lucid Diagnostics Inc
Currency: USD Updated: 2026-07-02Key Insights
Lucid Diagnostics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 94 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.95.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lucid Diagnostics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lucid Diagnostics Inc Highlights
StrengthsRisks
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 93.82% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.71M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.71M.
Undervalued
The company’s latest PE is -3.17, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.22M shares, increasing 5.35% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.54.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
3.950
Target Price
+276.19%
Upside Space
Lucid Diagnostics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lucid Diagnostics Inc Info
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Ticker SymbolLUCD
CompanyLucid Diagnostics Inc
CEOAklog (Lishan)
Websitehttps://www.luciddx.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Lucid Diagnostics Inc (LUCD)?
The current price of Lucid Diagnostics Inc (LUCD) is 1.07.
What is the symbol of Lucid Diagnostics Inc?
The ticker symbol of Lucid Diagnostics Inc is LUCD.
What is the 52-week high of Lucid Diagnostics Inc?
The 52-week high of Lucid Diagnostics Inc is 1.63.
What is the 52-week low of Lucid Diagnostics Inc?
The 52-week low of Lucid Diagnostics Inc is 0.90.
What is the market capitalization of Lucid Diagnostics Inc?
The market capitalization of Lucid Diagnostics Inc is 140.09M.
Is Lucid Diagnostics Inc (LUCD) currently rated as Buy, Hold, or Sell?
According to analysts, Lucid Diagnostics Inc (LUCD) has an overall rating of Buy, with a price target of 3.95.
What is the Earnings Per Share (EPS TTM) of Lucid Diagnostics Inc (LUCD)?
The Earnings Per Share (EPS TTM) of Lucid Diagnostics Inc (LUCD) is -0.69.